OliX Pharmaceuticals,Inc (226950.KQ)

KRW 50950.0

(-1.26%)

Total Debt Summary of OliX Pharmaceuticals,Inc

OliX Pharmaceuticals,Inc's latest annual total debt in 2023 was 39.35 Billion KRW , down -10.54% from previous year.
OliX Pharmaceuticals,Inc's latest quarterly total debt in 2024 Q1 was 46.82 Billion KRW , up 18.97% from previous quarter.
OliX Pharmaceuticals,Inc reported annual total debt of 43.99 Billion KRW in 2022, up 18.04% from previous year.
OliX Pharmaceuticals,Inc reported annual total debt of 37.27 Billion KRW in 2021, up 156.57% from previous year.
OliX Pharmaceuticals,Inc reported quarterly total debt of 47.74 Billion KRW for 2024 Q2, up 1.96% from previous quarter.
OliX Pharmaceuticals,Inc reported quarterly total debt of 44.64 Billion KRW for 2023 Q1, up 1.47% from previous quarter.

Annual Total Debt Chart of OliX Pharmaceuticals,Inc (2023 - 2015)

Historical Annual Total Debt of OliX Pharmaceuticals,Inc (2023 - 2015)

Year	Total Debt	Total Debt Growth
2023	39.35 Billion KRW	-10.54%
2022	43.99 Billion KRW	18.04%
2021	37.27 Billion KRW	156.57%
2020	14.52 Billion KRW	6425.51%
2019	222.61 Million KRW	0.0%
2018	- KRW	-100.0%
2017	1.4 Billion KRW	-19.54%
2016	1.74 Billion KRW	0.0%
2015	- KRW	0.0%

Year	Total Debt	Total Debt Growth
2024 Q1	46.82 Billion KRW	18.97%
2024 Q2	47.74 Billion KRW	1.96%
2023 Q1	44.64 Billion KRW	1.47%
2023 FY	39.35 Billion KRW	-10.54%
2023 Q3	44.31 Billion KRW	-2.51%
2023 Q2	45.46 Billion KRW	1.84%
2023 Q4	39.35 Billion KRW	-11.2%
2022 Q2	38.42 Billion KRW	1.53%
2022 FY	43.99 Billion KRW	18.04%
2022 Q4	43.99 Billion KRW	6.88%
2022 Q3	41.16 Billion KRW	7.12%
2022 Q1	37.85 Billion KRW	1.56%
2021 Q4	37.27 Billion KRW	122.62%
2021 Q1	15.33 Billion KRW	7.45%
2021 Q2	16.18 Billion KRW	5.58%
2021 Q3	16.74 Billion KRW	3.42%
2021 FY	37.27 Billion KRW	156.57%
2020 Q4	14.26 Billion KRW	4590.69%
2020 FY	14.52 Billion KRW	6425.51%
2020 Q1	217.39 Million KRW	5.05%
2020 Q2	469.49 Million KRW	115.97%
2020 Q3	304.17 Million KRW	-35.21%
2019 Q4	206.93 Million KRW	307.47%
2019 FY	222.61 Million KRW	0.0%
2019 Q3	50.78 Million KRW	80.38%
2019 Q2	28.15 Million KRW	-49.53%
2019 Q1	55.78 Million KRW	0.0%
2018 Q1	- KRW	0.0%
2018 Q4	- KRW	0.0%
2018 FY	- KRW	-100.0%
2017 FY	1.4 Billion KRW	-19.54%
2016 FY	1.74 Billion KRW	0.0%
2015 FY	- KRW	0.0%

Peer Total Debt Comparison of OliX Pharmaceuticals,Inc

Name	Total Debt	Total Debt Difference
HLB Co., Ltd.	62.7 Billion KRW	37.235%
iNtRON Biotechnology, Inc.	402.9 Million KRW	-9668.284%
BINEX Co., Ltd.	53.5 Billion KRW	26.445%
Bioneer Corporation	44.63 Billion KRW	11.834%
Anterogen.Co.,Ltd.	9.74 Billion KRW	-304.063%
MEDIPOST Co., Ltd.	52.33 Billion KRW	24.801%
CrystalGenomics, Inc.	32 Billion USD	-22.98%
Helixmith Co., Ltd	20.22 Billion KRW	-94.571%
Chabiotech Co.,Ltd.	449.63 Billion KRW	91.247%
Medy-Tox Inc.	82.83 Billion KRW	52.484%
Peptron, Inc.	9.13 Billion KRW	-330.936%
Amicogen, Inc.	149.59 Billion KRW	73.691%
Genexine, Inc.	67.42 Billion KRW	41.63%
HLB Therapeutics Co.,Ltd.	10.02 Billion KRW	-292.696%
LegoChem Biosciences, Inc.	12.64 Billion KRW	-211.275%
ALTEOGEN Inc.	83.76 Billion KRW	53.017%
PharmaResearch Co., Ltd.	34.3 Billion KRW	-14.722%
SillaJen, Inc.	9.69 Billion KRW	-305.887%
JETEMA, Co., Ltd.	130.49 Billion KRW	69.84%
Genomictree Inc.	1.83 Billion KRW	-2045.215%
MedPacto, Inc.	8.6 Billion KRW	-357.425%
D&D Pharmatech	8.13 Billion KRW	-383.844%
EASY BIO,Inc.	82.27 Billion KRW	52.165%
GI Innovation, Inc.	3.72 Billion KRW	-957.757%